Susquehanna International Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Susquehanna International Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Sell	32,600 -365,800	-92%	-$16.3M	﹤0.01%	7454
2025 Q4	$18.5M	Buy	398,400 +154,500	+63%	+$6.88M	﹤0.01%	2296
2025 Q3	$10.2M	Buy	+243,900	New	+$7.8M	﹤0.01%	3018
2025 Q1	–	Sell	-10,800	Closed	-$552K	–	12599
2024 Q4	$552K	Sell	10,800 -900	-8%	-$50.4K	﹤0.01%	8428
2024 Q3	$598K	Sell	11,700 -17,300	-60%	-$892K	﹤0.01%	8038
2024 Q2	$1.3M	Sell	29,000 -147,200	-84%	-$6.8M	﹤0.01%	5979
2024 Q1	$8.25M	Sell	176,200 -87,300	-33%	-$3.42M	﹤0.01%	2897
2023 Q4	$9.38M	Buy	263,500 +142,000	+117%	+$4.35M	﹤0.01%	2719
2023 Q3	$3.61M	Buy	+121,500	New	+$2.5M	﹤0.01%	4068

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Susquehanna International Group's CRNX Position: Q1 2026 in Review

Susquehanna International Group increased its Crinetics Pharmaceuticals (CRNX) stake by 38% in Q1 2026, buying an estimated $569K and bringing the position to 46,253 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #6575.

Susquehanna International Group first reported a position in CRNX in Q3 2021 and has held it in 19 quarters since. The position peaked at $10.7M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Susquehanna International Group held 46,253 shares of Crinetics Pharmaceuticals worth $1.68M as of Q1 2026.
Susquehanna International Group bought 12,742 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $569K.
Crinetics Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6575 holding.
Susquehanna International Group first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
Susquehanna International Group's Crinetics Pharmaceuticals position peaked at $10.7M in Q3 2025.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.